Tech Support

TECHNICAL SUPPORT
+1.800.674.3430

This line is for technical support.
For General Enquiries please click General Contact

Enroll Your Immuno-Oncology Agents in Our Next MuScreenTM Today

MuScreen is the first high throughput in vivo screen for evaluating immunotherapy and immune modulating compounds across both well-characterized syngeneic and unique tumor homograft models.

Agent efficacy is evaluated using syngeneic and/or tumor homograft model panels, with PD effects assessed using syngeneic models only. MuScreen is a cost-effective screening platform, with a free vehicle arm and shared cost of the positive control arm.

Select the Models and Study Design to Suit Your Program

Model Type Model  Features
Efficacy PD
US
China
US
China
Syngeneic Display immune heterogeneity and diversity observed in the clinic  
Tumor Homograft   Transplants of GEMM tumors into a syngeneic host, preserving original GEMM tumor molecular and histopathology and clinically relevant oncogenic driver mutations      

Immunotherapy treatment strategies using LAG3 including antagonistic checkpoint inhibitor antibodies and antigen presenting cell activation

2019 MuScreen Preset Timetable

Syngeneic

12 Model Efficacy and PD Mode
Study Site: CrownBio China
Registration Deadline
Study Initiation
April 25th
May 15th
July 15th  
August 15th
September 15th  
October 15th
 
6 Model Efficacy Mode
Study Site: CrownBio San Diego
Registration Deadline
Study Initiation
April 15th
May 15th
July 25th  
August 15th
October 15th  
November 15th
January 15th, 2020 
February 15th, 2020

Tumor Homograft

8 Model Efficacy Mode
Study Site: CrownBio China
Registration Deadline
Study Initiation
May 15th
June 15th
August 31st  
October 15th

Enroll Now!

Your privacy is important to us.
We'll never share your information.

SHARE THIS